Secondary Progressive Multiple Sclerosis Clinical Trial
Official title:
Evaluating the Effects of Functional Electrical Stimulation on Ambulation in Individuals With Secondary Progressive Multiple Sclerosis
| NCT number | NCT01647321 |
| Other study ID # | NA_00069253 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | July 2012 |
| Est. completion date | October 2019 |
| Verified date | March 2020 |
| Source | Johns Hopkins University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS) for which there are no existing therapies that alter the disease course. This research will utilize cutting edge functional electrical stimulation (FES) cycling technology with the goal of improving walking in individuals with SPMS. The investigators hypothesize that FES cycling will improve walking in subjects with SPMS.
| Status | Completed |
| Enrollment | 16 |
| Est. completion date | October 2019 |
| Est. primary completion date | October 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 68 Years |
| Eligibility |
Inclusion Criteria: - clinical diagnosis of secondary progressive multiple sclerosis - males and females between the ages of 18 and 65 years - Expanded disability status scale score between 5.0 and 7.0 - Able to consent to participate in study and are willing to undergo a lumbar puncture and blood draws - If on on Ampyra or anti-spasticity agent, must be on stable dose for 1 month prior to screening - No functional electrical stimulation use within 4 weeks - Participants must be medically stable with no recent (1 month or less) inpatient admission for acute medical or surgical issues Exclusion Criteria: - Uncontrolled hypertension or other significant cardiovascular disease as determined by investigator - History of epileptic seizures - Subjects who have a pacemaker - Relapse within thirty days prior to screening visit - Pregnancy - Subjects having a Stage 2 or greater sacral decubitus ulcer |
| Country | Name | City | State |
|---|---|---|---|
| United States | Johns Hopkins / Kennedy Krieger Institute | Baltimore | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| Johns Hopkins University | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in timed 25 foot walk from baseline to end of training | Here we will assess whether a subjects walking speed is improved following active cycling with functional electrical stimulation. Our prediction is that individuals will improve in their walking function following seated active cycling with functional electrical stimulation. | Participants are assessed at baseline (visit 1), one-month (visit 2), two-months (visit 3), three-months (visit 4), end of study (visit 5) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04239664 -
Acceptance Based Telephone Support When Transitioning to SPMS
|
N/A | |
| Active, not recruiting |
NCT04411641 -
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
|
Phase 3 | |
| Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
| Terminated |
NCT01416181 -
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
|
Phase 3 | |
| Withdrawn |
NCT01181089 -
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03471338 -
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
|
N/A | |
| Withdrawn |
NCT05029609 -
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
|
Phase 1 | |
| Completed |
NCT02228213 -
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Terminated |
NCT02296346 -
Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis
|
N/A | |
| Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
| Terminated |
NCT03283826 -
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02253264 -
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
|
Phase 1 | |
| Completed |
NCT01737372 -
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
|
N/A | |
| Completed |
NCT00257855 -
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT06292923 -
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
|
Phase 2 | |
| Active, not recruiting |
NCT01228396 -
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT03896217 -
Simvastatin in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02495766 -
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00813969 -
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
|
Phase 1 | |
| Completed |
NCT01077466 -
Natalizumab Treatment of Progressive Multiple Sclerosis
|
Phase 2 |